PTC518
Sponsors
Novartis Pharma AG, PTC Therapeutics Inc., Novartis Pharmaceuticals
Conditions
Huntington DiseaseHuntington's DiseaseHuntington’s Disease
Phase 2
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
CompletedNCT05358717
Start: 2022-06-03End: 2025-07-31Updated: 2026-06-16
A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington’s Disease
Active, not recruitingCTIS2023-504628-24-00
Start: 2023-10-31Target: 172Updated: 2025-10-27
A Phase 2a, Randomized, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects with Huntington’s Disease
CompletedCTIS2023-509835-26-00
Start: 2022-07-06End: 2025-05-23Target: 121Updated: 2025-06-20